BMS-986507 Combinations for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment, BMS-986507, for individuals with advanced solid tumors, such as certain types of lung and breast cancer. Researchers aim to assess the safety, effectiveness, and behavior of this treatment in the body. The trial includes different groups: one for specific lung cancer mutations, another for more general advanced lung cancer, and one for certain types of breast cancer. Ideal candidates have a measurable tumor and a life expectancy of at least three months. Participants should not have a history of severe infections or heart disease. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Do I need to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that the treatment BMS-986507, also known as izalontamab brengitecan, generally has a well-tolerated safety profile, with acceptable side effects. In one study, 44.1% of advanced cancer patients responded to the treatment, indicating effectiveness for many participants.
Although detailed safety data from human trials for BMS-986507 remains limited, its testing in both early and later trial phases suggests it has passed initial safety checks, often indicating that serious side effects are uncommon. Prospective trial participants should discuss potential side effects and benefits with the research team.12345Why are researchers excited about this trial's treatments?
Unlike the standard treatments for lung cancer, which typically involve chemotherapy, targeted therapy, or immunotherapy, BMS-986507 offers a novel approach. Researchers are excited about this treatment because it may work by targeting a new pathway or mechanism not addressed by existing therapies. This could potentially lead to improved outcomes for patients who do not respond well to current options, offering hope for a more effective and personalized treatment strategy.
What evidence suggests that this trial's treatments could be effective for lung cancer?
Research has shown that BMS-986507, also known as izalontamab brengitecan, yields promising results in treating certain cancers. In studies with patients who had advanced bladder cancer, nearly half experienced tumor shrinkage. Additionally, in 88.2% of these patients, the cancer did not progress. These findings suggest that BMS-986507 could effectively treat advanced solid tumors, including lung cancer. In this trial, participants will join one of the experimental groups to receive BMS-986507. This treatment combines an antibody with chemotherapy, targeting specific cancer cells to deliver chemotherapy directly, aiming for greater effectiveness with less harm to healthy cells.12346
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors, which can include various types of cancer that have spread beyond their original location. Specific eligibility details are not provided, but typically participants must meet certain health standards and may need to have tried other treatments first.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-986507 combinations to evaluate safety, tolerability, drug levels, and preliminary efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BMS-986507
Trial Overview
The study is testing the safety and effectiveness of combining a new drug called BMS-986507 with Osimertinib and Pembrolizumab in treating advanced cancers. It will look at how well patients tolerate the combination therapy and measure its impact on their tumors.
How Is the Trial Designed?
5
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania
Citations
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted ...
The FDA's decision was based on efficacy and safety data from three ongoing clinical trials: BL-B01D1-101 and BL-B01D1-203, conducted in China ...
2.
onclive.com
onclive.com/view/izalontamab-brengitecan-data-reinforce-the-value-of-adcs-in-advanced-urothelial-carcinomaIzalontamab Brengitecan Data Reinforce the Value of ...
Izalontamab brengitecan showed a 44.1% objective response rate and 88.2% disease control rate in advanced urothelial carcinoma patients. The ...
Study of Izalontamab Brengitecan (BMS-986507) Versus ...
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With ...
News
SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug ...
ESMO 2025 – iza-bren's US backing comes with toxicity
The trial, described as iza-bren's first global study to yield data, mostly concerned lung cancer, plus several other heavily pretreated tumours ...
ESMO 2025: First Global Phase I Results of Izalontamab ...
The US-Lung-101 study (NCT05983432), a global, multi-center, phas 1 study, evaluated the safety and efficacy of Izalontamab Brengitecan in ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.